Posted by Michael Wonder on 03 Mar 2022
Harpoon Therapeutics receives FDA fast track designation for HPN217
2 March 2022 - Harpoon Therapeutics today announced that the U.S. FDA has granted fast track designation to HPN217, a BCMA targeting TriTAC, for the treatment of patients with relapsed, refractory multiple myeloma who have received at least four lines of therapy.
A Phase 1/2 clinical trial is currently on-going for HPN217 in the relapsed, refractory multiple myeloma patient population.
